Bryn Mawr Capital Management LLC Buys 2,672 Shares of Novo Nordisk A/S (NYSE:NVO)

Bryn Mawr Capital Management LLC increased its stake in Novo Nordisk A/S (NYSE:NVO) by 36.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,023 shares of the company’s stock after purchasing an additional 2,672 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Novo Nordisk A/S were worth $1,037,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. CNB Bank bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $26,000. Pacific Center for Financial Services raised its holdings in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the period. Valued Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $28,000. Copeland Capital Management LLC raised its holdings in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock worth $26,000 after purchasing an additional 141 shares during the period. Finally, Bell Investment Advisors Inc raised its holdings in Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on NVO. UBS Group began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating on the stock. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Stock Up 0.9 %

NVO opened at $126.86 on Friday. The company has a fifty day moving average price of $126.86 and a 200-day moving average price of $111.98. The firm has a market capitalization of $569.29 billion, a P/E ratio of 46.90, a price-to-earnings-growth ratio of 2.10 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. Equities research analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were given a $0.664 dividend. The ex-dividend date was Friday, March 22nd. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. Novo Nordisk A/S’s payout ratio is 49.17%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.